(Q52909563)

9 May 2018

title

Making and circumventing tolerance to cancer. (English)

1 reference

9 May 2018

author name string

Thomas Kammertoens

series ordinal

1

1 reference

9 May 2018

Thomas Blankenstein

series ordinal

2

1 reference

9 May 2018

language of work or name

English

0 references

publication date

1 September 2009

1 reference

9 May 2018

European Journal of Immunology

published in

1 reference

9 May 2018

volume

39

1 reference

9 May 2018

issue

9

1 reference

9 May 2018

page(s)

2345-2353

1 reference

9 May 2018

Tumor Development after 3-Methylcholanthrene in Immunologically Deficient Athymic-Nude Mice

cites work

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

Mini-review: overcoming tumor-intrinsic resistance to immune effector function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

Maximizing mouse cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

Some recollections of Peter Gorer and his work on this fiftieth anniversary of his discovery of H-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

Cancer immunotherapy and preclinical studies: why we are not wasting our time with animal experiments

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

Cancer immunotherapy: moving beyond current vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

Immunotherapy: target the stroma to hit the tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

Bystander elimination of antigen loss variants in established tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

Friends or foes - bipolar effects of the tumour stroma in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

Immunosuppressive strategies that are mediated by tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

Chemical carcinogens as foreign bodies and some pitfalls regarding cancer immune surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

Adaptive immunity maintains occult cancer in an equilibrium state

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

NKG2D function protects the host from tumor initiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

Inhibition of methylcholanthrene-induced carcinogenesis by an interferon gamma receptor-dependent foreign body reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

CD4+ CD25+ regulatory T lymphocytes inhibit microbially induced colon cancer in Rag2-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

Deficiencies of GM-CSF and Interferon γ Link Inflammation and Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

Do autochthonous tumors interfere with effector T cell responses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

Timely immunization subverts the development of peripheral nonresponsiveness and suppresses tumor development in simian virus 40 tumor antigen-transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus In vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

Progress in human tumour immunology and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

Graft-versus-leukemia reactions in allogeneic chimeras

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

Adoptive cell therapy for the treatment of patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

Adoptive tumor therapy with T lymphocytes enriched through an IFN-gamma capture assay.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

Preclinical development of T cell receptor gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

Immunotherapy with CTLs restricted by nonself MHC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

Dendritic cells pulsed with RNA encoding allogeneic MHC and antigen induce T cells with superior antitumor activity and higher TCR functional avidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

In vitro evolution of a T cell receptor with high affinity for peptide/MHC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

Designer T cells by T cell receptor replacement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

TCR transgenes and transgene cassettes for TCR gene therapy: status in 2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

Antigen choice in adoptive T-cell therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

Costimulation tunes tumor-specific activation of redirected T cells in adoptive immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

The T-body approach: redirecting T cells with antibody specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

Induced sensitization of tumor stroma leads to eradication of established cancer by T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

Requirements for effective antitumor responses of TCR transduced T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

Bcl-2 overexpression enhances tumor-specific T-cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

Facilitating matched pairing and expression of TCR chains introduced into human T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

Grafting primary human T lymphocytes with cancer-specific chimeric single chain and two chain TCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

Alpha beta T cell receptor transfer to gamma delta T cells generates functional effector cells without mixed TCR dimers in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

Increasing functional avidity of TCR-redirected T cells by removing defined N-glycosylation sites in the TCR constant domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

Dual T cell receptor expressing CD8+ T cells with tumor- and self-specificity can inhibit tumor growth without causing severe autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

Human TCR that incorporate CD3zeta induce highly preferred pairing between TCRalpha and beta chains following gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

Equilibrium between host and cancer caused by effector T cells killing tumor stroma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

A safeguard eliminates T cell receptor gene-modified autoreactive T cells after adoptive transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

An inducible caspase 9 safety switch can halt cell therapy-induced autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

Effect of Germ-free Status and Antilymphocyte Serum on Induction of Various Tumours in Mice by a Chemical Carcinogen given at Birth

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

Antigenicity of murine skin tumors induced by ultraviolet light

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

7 January 2021

MCA Sarcomas Induced in scid Mice are More Immunogenic than MCA Sarcomas Induced in Congenic, Immunocompetent Mice

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

7 January 2021

A cancer immunosurveillance controversy

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

7 January 2021

IMMUNOLOGICAL FACTORS IN THE PROCESS OF CARCINOGENESIS

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

7 January 2021

Early immunization induces persistent tumor-infiltrating CD8+ T cells against an immunodominant epitope and promotes lifelong control of pancreatic tumor progression in SV40 tumor antigen transgenic mice

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

7 January 2021

Adoptive immunotherapy for EBV-associated malignancies

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

7 January 2021

Improving T cell therapy for cancer

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

7 January 2021

Cooperation of Human Tumor-Reactive CD4+ and CD8+ T Cells after Redirection of Their Specificity by a High-Affinity p53A2.1-Specific TCR

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

7 January 2021

Reversible MHC multimer staining for functional isolation of T-cell populations and effective adoptive transfer

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

7 January 2021

Molecular design of the Calphabeta interface favors specific pairing of introduced TCRalphabeta in human T cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

7 January 2021

Cutting Edge: CD8+ Effector T Cells Reject Tumors by Direct Antigen Recognition but Indirect Action on Host Cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

7 January 2021

Balancing between antitumor efficacy and autoimmune pathology in T-cell-mediated targeting of carcinoembryonic antigen

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200939612

7 January 2021

Identifiers

DOI

10.1002/EJI.200939612

1 reference

9 May 2018

1 reference

9 May 2018